tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol. 2020 May 2. doi: 10.1111/jdv.16571. [Epub ahead of print]
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Balestri R[SUP]1[/SUP], Rech G[SUP]1[/SUP], Girardelli CR[SUP]1[/SUP].
Author information
Abstract
we read with great interest the article entitled "SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor" published by Messina F. and Piaserico S. in the JEADV.[SUP]1[/SUP] This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor.
This article is protected by copyright. All rights reserved.
KEYWORDS:
IL17-inhibitor; SARS-CoV-2; COVID-19; psoriasis; ixekizumab
PMID:32358791DOI:10.1111/jdv.16571
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Balestri R[SUP]1[/SUP], Rech G[SUP]1[/SUP], Girardelli CR[SUP]1[/SUP].
Author information
Abstract
we read with great interest the article entitled "SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor" published by Messina F. and Piaserico S. in the JEADV.[SUP]1[/SUP] This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor.
This article is protected by copyright. All rights reserved.
KEYWORDS:
IL17-inhibitor; SARS-CoV-2; COVID-19; psoriasis; ixekizumab
PMID:32358791DOI:10.1111/jdv.16571